Sridhar Duvvuri

机构：Cerevel Therapeutics (United States)

发表论文 62 篇 · 总被引 1804 次 · h-index 23

代表论文

• Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial (2022 · The Lancet · 被引 113)
• PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial (2020 · Therapeutic Advances in Neurological Disorders · 被引 52)
• Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated (2018 · Neurology and Therapy · 被引 50)
• Dopaminergic D1 Receptor Stimulation Affects Effort and Risk Preferences (2019 · Biological Psychiatry · 被引 48)
• Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson’s Disease (2023 · CNS & Neurological Disorders - Drug Targets · 被引 44)
• Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment (2023 · Clinical Parkinsonism & Related Disorders · 被引 44)